InFlectis BioScience is leveraging its leading expertise in the cellular defense system against misfolded proteins and drug discovery to identify and develop small molecules which modulate key proteins involved in misfolded protein disorders. Endoplasmic Reticulum (ER) proteostasis is vital for cellular function and cell survival. Many different perturbations can alter the folding capacity of the ER and may cause accumulation of unfolded or misfolded proteins inside the ER, a cellular condition referred to as ER stress. To safeguard proteostasis, the mammalian ER has a complex machinery to maintain the integrity of cells. This adaptive programme is called the unfolded protein response (UPR).

UK Research & Innovation (doing business as United Kingdom Research & Innovation) is a private company headquartered in London, UK. The firm provides science and technology research services.\nThe company says this about itself: Innovate UK is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government. We drive productivity and economic growth by supporting businesses to develop and realise the potential of new ideas, including those from the UK’s world-class research base.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

Forschungszentrum Jülich ("Jülich Research Centre") is a member of the Helmholtz Association of German Research Centres and is one of the largest interdisciplinary research centres in Europe. It was founded on 11 December 1956 by the state of North Rhine-Westphalia as a registered association, before it became "Kernforschungsanlage Jülich GmbH" or Nuclear Research Centre Jülich in 1967. In 1990, the name of the association was changed to "Forschungszentrum Jülich GmbH". It has close collaborations with RWTH Aachen in the form of Jülich-Aachen Research Alliance (JARA).

Central Glass Co., Ltd. engages in production, fabrication, sale and purchase of glass and chemical products. It operates through the following segments: Glass Business and Chemicals Business. The Glass Business segment manufactures and distributes architectural glass, glass products for automobiles and electronic materials. The Chemicals Business segment produces and sells chemical and fine chemical products, fertilizer, and glass fiber. The company was founded on October 10, 1936 and is headquartered in Tokyo, Japan.

betaSENSE is a biotechnology research company that specializes in protein diagnostic services in the field of protein science.

Wren Therapeutics is a biopharmaceutical company based in Cambridge UK, focused on drug discovery and development for protein misfolding diseases, which include Alzheimer’s and Parkinson’s diseases, type-2 diabetes, and many rare forms of amyloidosis. Wren’s proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. Wren is using this platform to develop small molecule therapeutics for multiple protein misfolding diseases, including major neurological and rare disorders.

Arizona Board of Regents oversees college activities. The company was founded in 1864 and is headquartered in Phoenix, AZ.

Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models. They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugs currently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept.

GestVision, Inc. is commercializing a point of care diagnostic test for preeclampsia. The pregnancy-related condition is often characterized by the symptoms of high blood pressure and protein in the urine. Left untreated, the condition can lead to seizures and even death. Preeclampsia is an equal opportunity problem and is of concern in both developed and developing nations. The US is not immune and sees preeclampsia as a growing problem.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Riken Corp. engages in the manufacture and sale of engine and vehicular components. It operates through the Automotive and Machinery Parts, and Others segments. The Automotive and Machinery Parts segment deals with the company's core products such as piston rings, camshafts, seal rings for transmissions, high-grade cast iron products, and valve lifters. The Others segment includes plumbing equipment business, Electromagnetic Compatibility (EMC) business, and thermal engineering business, The company was founded by Masatoshi Okochi in November 1927 and is headquartered in Tokyo, Japan.

Akero Therapeutics is committed to providing meaningful treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the liver and liver cell damage resulting in fibrosis, cirrhosis, liver failure, and death. The company is developing pioneering medicines designed to restore metabolic balance and halt NASH progression. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential best-in-class treatment for NASH. The AKR-001 builds upon two decades of work on FGF21 biology. It is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

TREVENTIS Corporation is dedicated to treating and preventing protein misfolding diseases. We utilize a proprietary, patent-pending discovery engine – Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets. Our lead program focuses on anti-misfolding small molecules in tauopathy (3R, 4R, familial mutations and mixed) with relevance to Alzheimer’s disease. We have further CCM-driven efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology platform.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.